What is GoodRx?
Founded in 2011 and headquartered in Santa Monica, California, GoodRx operates a sophisticated price comparison platform designed to mitigate the complexities of prescription drug costs in the United States. By providing consumers with curated, geographically relevant pricing data, the company empowers patients to access negotiated rates that would otherwise remain opaque. Beyond its core price comparison engine, GoodRx has diversified its operational footprint to include subscription-based models, pharmaceutical manufacturer solutions, and the GoodRx Care telehealth platform. This multi-faceted approach allows the company to address the needs of various stakeholders, including pharmacy benefit managers who manage complex formulary transactions, thereby positioning GoodRx as an essential utility in the modern healthcare ecosystem.
How much funding has GoodRx raised?
GoodRx has raised a total of $2.2B across 3 funding rounds:
Angel/Seed
$1M
Stock Offering
$1.1B
Stock Offering
$1.1B
Angel/Seed (2012): $1M with participation from Lerer Ventures, Highland Capital Partners, and SV Angel
Stock Issuance/Offering (2020): $1.1B, investors not publicly disclosed
Stock Issuance/Offering (2020): $1.1B, investors not publicly disclosed
Key Investors in GoodRx
Lerer Ventures
Kenneth Lerer Associates LLC is a prominent venture capital and private equity firm that provides early-stage support to innovative companies.
Highland Capital Partners
Highland Capital Partners is a venture capital firm with a significant track record of supporting startups through to IPO, managing over $7 billion in assets.
SV Angel
SV Angel is a long-term investment firm dedicated to supporting founders by providing strategic insights and a vast network to help companies scale effectively.
What's next for GoodRx?
With the support of its recent capital injection, GoodRx is well-positioned to deepen its integration within the broader healthcare infrastructure. The strategic focus is expected to shift toward enhancing the interoperability of its telehealth services and expanding its reach into new pharmaceutical manufacturer partnerships. As the company navigates the evolving regulatory environment surrounding drug pricing, its ability to leverage data-driven insights will be paramount. Investors and market analysts will likely monitor how the firm utilizes its current liquidity to defend its market share against emerging competitors while simultaneously driving user adoption across its digital health portfolio. The company's long-term growth strategy remains anchored in its ability to simplify the patient journey while maintaining its status as a trusted intermediary in the prescription drug market.
See full GoodRx company page
